Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Collplant Holdings ( (CLGN) ) is now available.
On December 31, 2025, CollPlant Biotechnologies Ltd. held its Annual and Extraordinary General Meeting of Shareholders in which investors approved all four proposals on the agenda, each receiving the requisite majority. The shareholder approvals, which followed the company’s November 26, 2025 notice convening the meeting, clear the way for CollPlant to implement its proposed corporate and governance actions without opposition, supporting continuity in management’s strategic plans and regulatory compliance as a foreign private issuer.
The most recent analyst rating on (CLGN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Underperform.
Collplant Holdings’ overall stock score is driven by its poor financial performance and weak technical indicators. The company’s significant financial challenges, including revenue and cash flow declines, and negative profit margins, are the primary concerns. Additionally, bearish technical signals and an unattractive valuation further contribute to the low score.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd. is an Israel-based biotechnology company. The firm operates as a foreign private issuer listed in the United States and files reports with the Securities and Exchange Commission under the Securities Exchange Act of 1934, reflecting its presence in global capital markets.
Average Trading Volume: 35,011
Technical Sentiment Signal: Sell
Current Market Cap: $18.31M
For an in-depth examination of CLGN stock, go to TipRanks’ Overview page.